e-ISSN: Pending
Negative / Null Result ReportOpen accessDiseases of the circulatory (Cardiovascular) system

IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial

Pankaj Puar; Nikhil Mistry; Kim A. Connelly; Andrew T. Yan; Adrian Quan; Hwee Teoh; Yi Pan; Raj Verma · 2023 · ESC Heart Failure

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Abstract Aims Given recent suggestions that serum levels of insulin‐like growth factor‐binding protein 7 (IGFBP7) may identify patients who derive greater cardiorenal benefits from treatment with sodium‐glucose transport 2 inhibitors (SGLT2i), this exploratory sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized controlled trial evaluated the association between serum levels of IGFBP7 and empagliflozin‐mediated left ventricular mass regression. Methods and results The EMPA‐HEART CardioLink‐6 trial used gold‐standard cardiac magnetic resonance imaging to detect change in left ventricular mass

Abstract by Pankaj Puar; Nikhil Mistry; Kim A. Connelly; Andrew T. Yan; Adrian Quan; Hwee Teoh; Yi Pan; Raj Verma, ESC Heart Failure (2023) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.1002/ehf2.14335